Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows:
William Blair Virtual BioTech Conference
Panel Session: Advancements in Renal Disease: Thursday, August 6, 2020 at 3:00pm EDT
Presenter: Noreen Henig, MD, Chief Medical Officer
BTIG Virtual Biotechnology Conference 2020
Presentation: Tuesday, August 11, 2020 at 1:30pm EDT
Presenter: John Fowler, Chief Executive Officer
The panel and presentation will be webcast live and may be accessed on the “Events & Presentations” section of the Company’s website at https://investors.kezarlifesciences.com/. Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conference.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from Kezar’s protein secretion program, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.
Source: Kezar Life Sciences, Inc.
Released August 3, 2020